NIH recombinant DNA Advisory Committee continues to ponder adverse event associated with AAV gene therapy trial.
Williams
David A
DA
D026683:Advisory Committees; D001172:Arthritis, Rheumatoid / Q000628:therapy; D000229:Dependovirus / Q000235:genetics*; D015316:Genetic Therapy / Q000009:adverse effects* / Q000592:standards; D006801:Humans; D009316:National Institutes of Health (U.S.); D014481:United States